• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organovo Holdings (NQ: ONVO )

0.4020 -0.0410 (-9.26%)
Streaming Delayed Price Updated: 10:22 AM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organovo Holdings

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024
From Organovo, Inc.
Via GlobeNewswire
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024 
From Organovo, Inc.
Via GlobeNewswire
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 08, 2024
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
From Organovo, Inc.
Via GlobeNewswire
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024
From Organovo, Inc.
Via GlobeNewswire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024
From Organovo, Inc.
Via GlobeNewswire
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023
From Organovo, Inc.
Via GlobeNewswire
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023
From Organovo, Inc.
Via GlobeNewswire
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023
From Organovo, Inc.
Via GlobeNewswire
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023
From Organovo, Inc.
Via GlobeNewswire
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces FXR Program
March 21, 2023
Lead Molecule Poised for Phase 2 in IBD 
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022
From Organovo, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap